Andere Sprachen Entera Bio Ltd.

Aktien

A2JQXP

IL0011429839

ENTX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
1,98 ^USD	-1,00 %		-0,50 %	+230,00 %

08.04.	Entera Bio Ltd. gibt die Veröffentlichung der Daten der Phase-2-Studie mit oralen PTH(1-34)-Peptidtabletten (EB613) im Journal of Bone and Mineral Research bekannt	CI
26.03.	Entera Bio Ltd. gibt wichtigen regulatorischen Meilenstein für orales PTH(1-34) Peptid (EB613) Phase 3 Programm bekannt: FDA-Entscheidung über die Eignung von BMD als Surrogat-Endpunkt für Osteoporose-Medikamente wird innerhalb von 10 Monaten erwartet	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research	08.04.
Entera Bio Ltd. Announces Publication of Oral PTH(1-34) Peptide Tablets Phase 2 Trial Data in the Journal of Bone and Mineral Research	08.04.
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months	26.03.
Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months	26.03.
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	20.03.
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	20.03.
Entera Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	08.03.
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates	08.03.
Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement	04.03.
Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	30.01.
Top Premarket Gainers	18.01.
Top Premarket Gainers	17.01.
Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule	03.01.
Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025	26.12.
Entera Bio Ltd. announced that it has received $6.610594 million in funding	22.12.
Entera Bio Ltd. announced that it expects to receive $6.610594 million in funding	20.12.
Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform	29.11.
Entera Bio Ltd. Announces Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform	29.11.
Entera Bio Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14.11.
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development	14.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Entera Bio Ltd.

Aktien

A2JQXP

IL0011429839

ENTX

Andere Sprachen

Filter